Evaluation of MicroRNA-122 as a Biomarker for Chronic Hepatitis C Infection and as a Predictor for Treatment Response to Direct-Acting Antivirals

Naglaa S Elabd,1 Safaa I Tayel,2 Moamena S Elhamouly,1 Shaimaa A Hassanein,3 Samar M Kamaleldeen,4 Fatma E Ahmed,5 Mahmoud Rizk,6 Abdelnaser A Gadallah,7 Soma E Ajlan,8 Ahmed S Sief9 1Tropical Medicine Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt; 2Medical Biochemistry and M...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Elabd NS, Tayel SI, Elhamouly MS, Hassanein SA, Kamaleldeen SM, Ahmed FE, Rizk M, Gadallah AA, Ajlan SE, Sief AS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	chc fibroscan microrna- 122 daas Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/7ec437207865467b8d245a2264218463
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7ec437207865467b8d245a2264218463
record_format	dspace
spelling	oai:doaj.org-article:7ec437207865467b8d245a22642184632021-12-02T13:34:19ZEvaluation of MicroRNA-122 as a Biomarker for Chronic Hepatitis C Infection and as a Predictor for Treatment Response to Direct-Acting Antivirals1179-1535https://doaj.org/article/7ec437207865467b8d245a22642184632021-03-01T00:00:00Zhttps://www.dovepress.com/evaluation-of-microrna-122-as-a-biomarker-for-chronic-hepatitis-c-infe-peer-reviewed-article-HMERhttps://doaj.org/toc/1179-1535Naglaa S Elabd,1 Safaa I Tayel,2 Moamena S Elhamouly,1 Shaimaa A Hassanein,3 Samar M Kamaleldeen,4 Fatma E Ahmed,5 Mahmoud Rizk,6 Abdelnaser A Gadallah,7 Soma E Ajlan,8 Ahmed S Sief9 1Tropical Medicine Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt; 2Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt; 3Diagnostic Radiology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt; 4Clinical Pathology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt; 5Clinical Pharmacology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt; 6Internal Medicine Department, Faculty of Medicine, Banha University, Banha, Egypt; 7Internal Medicine Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt; 8Microbiology and Immunology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt; 9Hepatology and Gastroenterology Department, Shebin Elkom Teaching Hospital, Menoufia, EgyptCorrespondence: Safaa I TayelMedical Biochemistry and Molecular Biology Department, Faculty of Medicine, Menoufia University, Shebin El-Kom, Menoufia, 32511, EgyptTel +20 1003383097Email drsafaa_tayel@yahoo.comBackground: Treatment response to antiviral drugs is a challenging issue in patients with chronic hepatitis C virus (HCV) infection. Although microRNA-122 represents the majority of the microRNA content in hepatic tissues, few studies have evaluated its role in the treatment response, so we aimed to study its role in chronic HCV patients and in predicting the treatment response to direct-acting antivirals (DAAs).Methods: The study included 125 chronic HCV patients (89 naïve and 36 with a prior failed peginterferon/ribavirin response) and 50 apparently healthy subjects. Complete blood count, liver function, α-fetoprotein, lipid profiles, serum creatinine, abdominal ultrasound, and FibroScan® were assessed. Viral markers, HCV antibodies, and hepatitis B surface antigen were measured by enzyme-linked fluorescent immunoassay, with quantitative estimation of HCV RNA and microRNA-122 levels by real-time PCR.Results: The microRNA-122 level in HCV patients (those with a sustained virologic response 12 weeks after finishing therapy [SVR12] and non-responders) was significantly increased compared with controls and expressed more in non-responders versus SVR12 (p=0.042). ROC curve analysis of microRNA-122 for differentiating HCV patients from healthy controls revealed that a cut-off point of > 1.45 had a sensitivity of 67.20%, specificity of 94.0%, AUC=0.861, and p< 0.001; and for predicting response to treatment a cut-off point ≤ 5.66 could significantly (p=0.022) predict the occurrence of SVR, with a sensitivity of 60.34%, specificity of 66.67%, and AUC=0.729. Logistic regression analysis showed significant values for microRNA-122 in multivariate and univariate analysis for the prediction of response to DAAs.Conclusion: The results demonstrated the possible function of microRNA-122 as an indicative tool for distinguishing chronic HCV patients from controls and in the assessment of the therapeutic reaction to DAAs.Keywords: CHC, FibroScan, microRNA-122, DAAsElabd NSTayel SIElhamouly MSHassanein SAKamaleldeen SMAhmed FERizk MGadallah AAAjlan SESief ASDove Medical Pressarticlechcfibroscanmicrorna- 122daasDiseases of the digestive system. GastroenterologyRC799-869ENHepatic Medicine: Evidence and Research, Vol Volume 13, Pp 9-23 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	chc fibroscan microrna- 122 daas Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	chc fibroscan microrna- 122 daas Diseases of the digestive system. Gastroenterology RC799-869 Elabd NS Tayel SI Elhamouly MS Hassanein SA Kamaleldeen SM Ahmed FE Rizk M Gadallah AA Ajlan SE Sief AS Evaluation of MicroRNA-122 as a Biomarker for Chronic Hepatitis C Infection and as a Predictor for Treatment Response to Direct-Acting Antivirals
description	Naglaa S Elabd,1 Safaa I Tayel,2 Moamena S Elhamouly,1 Shaimaa A Hassanein,3 Samar M Kamaleldeen,4 Fatma E Ahmed,5 Mahmoud Rizk,6 Abdelnaser A Gadallah,7 Soma E Ajlan,8 Ahmed S Sief9 1Tropical Medicine Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt; 2Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt; 3Diagnostic Radiology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt; 4Clinical Pathology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt; 5Clinical Pharmacology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt; 6Internal Medicine Department, Faculty of Medicine, Banha University, Banha, Egypt; 7Internal Medicine Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt; 8Microbiology and Immunology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt; 9Hepatology and Gastroenterology Department, Shebin Elkom Teaching Hospital, Menoufia, EgyptCorrespondence: Safaa I TayelMedical Biochemistry and Molecular Biology Department, Faculty of Medicine, Menoufia University, Shebin El-Kom, Menoufia, 32511, EgyptTel +20 1003383097Email drsafaa_tayel@yahoo.comBackground: Treatment response to antiviral drugs is a challenging issue in patients with chronic hepatitis C virus (HCV) infection. Although microRNA-122 represents the majority of the microRNA content in hepatic tissues, few studies have evaluated its role in the treatment response, so we aimed to study its role in chronic HCV patients and in predicting the treatment response to direct-acting antivirals (DAAs).Methods: The study included 125 chronic HCV patients (89 naïve and 36 with a prior failed peginterferon/ribavirin response) and 50 apparently healthy subjects. Complete blood count, liver function, α-fetoprotein, lipid profiles, serum creatinine, abdominal ultrasound, and FibroScan® were assessed. Viral markers, HCV antibodies, and hepatitis B surface antigen were measured by enzyme-linked fluorescent immunoassay, with quantitative estimation of HCV RNA and microRNA-122 levels by real-time PCR.Results: The microRNA-122 level in HCV patients (those with a sustained virologic response 12 weeks after finishing therapy [SVR12] and non-responders) was significantly increased compared with controls and expressed more in non-responders versus SVR12 (p=0.042). ROC curve analysis of microRNA-122 for differentiating HCV patients from healthy controls revealed that a cut-off point of > 1.45 had a sensitivity of 67.20%, specificity of 94.0%, AUC=0.861, and p< 0.001; and for predicting response to treatment a cut-off point ≤ 5.66 could significantly (p=0.022) predict the occurrence of SVR, with a sensitivity of 60.34%, specificity of 66.67%, and AUC=0.729. Logistic regression analysis showed significant values for microRNA-122 in multivariate and univariate analysis for the prediction of response to DAAs.Conclusion: The results demonstrated the possible function of microRNA-122 as an indicative tool for distinguishing chronic HCV patients from controls and in the assessment of the therapeutic reaction to DAAs.Keywords: CHC, FibroScan, microRNA-122, DAAs
format	article
author	Elabd NS Tayel SI Elhamouly MS Hassanein SA Kamaleldeen SM Ahmed FE Rizk M Gadallah AA Ajlan SE Sief AS
author_facet	Elabd NS Tayel SI Elhamouly MS Hassanein SA Kamaleldeen SM Ahmed FE Rizk M Gadallah AA Ajlan SE Sief AS
author_sort	Elabd NS
title	Evaluation of MicroRNA-122 as a Biomarker for Chronic Hepatitis C Infection and as a Predictor for Treatment Response to Direct-Acting Antivirals
title_short	Evaluation of MicroRNA-122 as a Biomarker for Chronic Hepatitis C Infection and as a Predictor for Treatment Response to Direct-Acting Antivirals
title_full	Evaluation of MicroRNA-122 as a Biomarker for Chronic Hepatitis C Infection and as a Predictor for Treatment Response to Direct-Acting Antivirals
title_fullStr	Evaluation of MicroRNA-122 as a Biomarker for Chronic Hepatitis C Infection and as a Predictor for Treatment Response to Direct-Acting Antivirals
title_full_unstemmed	Evaluation of MicroRNA-122 as a Biomarker for Chronic Hepatitis C Infection and as a Predictor for Treatment Response to Direct-Acting Antivirals
title_sort	evaluation of microrna-122 as a biomarker for chronic hepatitis c infection and as a predictor for treatment response to direct-acting antivirals
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/7ec437207865467b8d245a2264218463
work_keys_str_mv	AT elabdns evaluationofmicrorna122asabiomarkerforchronichepatitiscinfectionandasapredictorfortreatmentresponsetodirectactingantivirals AT tayelsi evaluationofmicrorna122asabiomarkerforchronichepatitiscinfectionandasapredictorfortreatmentresponsetodirectactingantivirals AT elhamoulyms evaluationofmicrorna122asabiomarkerforchronichepatitiscinfectionandasapredictorfortreatmentresponsetodirectactingantivirals AT hassaneinsa evaluationofmicrorna122asabiomarkerforchronichepatitiscinfectionandasapredictorfortreatmentresponsetodirectactingantivirals AT kamaleldeensm evaluationofmicrorna122asabiomarkerforchronichepatitiscinfectionandasapredictorfortreatmentresponsetodirectactingantivirals AT ahmedfe evaluationofmicrorna122asabiomarkerforchronichepatitiscinfectionandasapredictorfortreatmentresponsetodirectactingantivirals AT rizkm evaluationofmicrorna122asabiomarkerforchronichepatitiscinfectionandasapredictorfortreatmentresponsetodirectactingantivirals AT gadallahaa evaluationofmicrorna122asabiomarkerforchronichepatitiscinfectionandasapredictorfortreatmentresponsetodirectactingantivirals AT ajlanse evaluationofmicrorna122asabiomarkerforchronichepatitiscinfectionandasapredictorfortreatmentresponsetodirectactingantivirals AT siefas evaluationofmicrorna122asabiomarkerforchronichepatitiscinfectionandasapredictorfortreatmentresponsetodirectactingantivirals
_version_	1718392804541988864

Evaluation of MicroRNA-122 as a Biomarker for Chronic Hepatitis C Infection and as a Predictor for Treatment Response to Direct-Acting Antivirals

Ejemplares similares